ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma

Zeng, Yu; Cai, Yonghua; Chai, Peng; Mao, Yangqi; Chen, Yanwen; Wang, Li; Zeng, Kunlin; Zhan, Ziling; Xie, Yuxin; Li, Cuiying; Zhan, Hongchao; Zhao, Liqian; Chen, Xiaoxia; Zhu, Xiaoxia; Liu, Yu; Chen, Ming*; Song, Ye*; Zhou, Aidong*南方医科大学; 上海交通大学; y
Frontiers in Immunology2022-8-3DOI: 10.3389/fimmu.2022.961933
4被引17阅读
引用收藏
分享

摘要

BackgroundPyroptosis is a critical type of programmed cell death that is strongly associated with the regulation of tumor and immune cell functions. However, the role of pyroptosis in tumor progression and remodeling of the tumor microenvironment in gliomas has not been extensively studied. Thus, in this study, we aimed to establish a comprehensive pyroptosis-related signature and uncover its potential clinical application in gliomas. MethodsThe TCGA glioma cohort was obtained and divided into training and internal validation cohorts, while the CGGA glioma cohort was used as an external validation cohort. Unsupervised consensus clustering was performed to identify pyroptosis-related expression patterns. A Cox regression analysis was performed to establish a pyroptosis-related risk signature. Real-time quantitative PCR was performed to analyze the expression of signature genes in glioma tissues. Immune infiltration was analyzed and validated by immunohistochemical staining. The expression patterns of signature genes in different cell types were analyzed using single-cell RNA sequencing data. Finally, therapeutic responses to chemotherapy, immunotherapy, and potential small-molecule inhibitors were investigated. ResultsPatients with glioma were stratified into clusters 1 and 2 based on the expression patterns of pyroptosis-related genes. Cluster 2 showed a longer overall (P<0.001) and progression-free survival time (P<0.001) than Cluster 1. CD8+ T cell enrichment was observed in Cluster 1. A pyroptosis-related risk signature (PRRS) was then established. The high PRRS group showed a significantly poorer prognosis than the low PRRS group in the training cohort (P<0.001), with validation in the internal and external validation cohorts. Immunohistochemical staining demonstrated that CD8+ T cells were enriched in high PRRS glioma tissues. PRRS genes also showed cell-specific expression in tumor and immune cells. Moreover, the high PRRS risk group showed higher temozolomide sensitivity and increased response to anti-PD1 treatment in a glioblastoma immunotherapy cohort. Finally, Bcl-2 inhibitors were screened as candidates for adjunct immunotherapy of gliomas. ConclusionThe pyroptosis-related signature established in this study can be used to reliably predict clinical outcomes and immunotherapy responses in glioma patients. The correlation between the pyroptosis signature and the tumor immune microenvironment may be used to further guide the sensitization of glioma patients to immunotherapy.

学科与关键词

关键词
gliomapyroptosisprognosistumor-associated microenvironmentimmunotherapysmall molecular inhibitor
相关
加载中…
  • Construction and Verification of a Novel Pyroptosis-Related lncRNA Signature Associated with Immune Landscape in Gliomas
    Feng, Xiaoqiang; Chen, Yuehua; Liu, Xuanyu; Zhong, Zhihui; Liu, Yanjun*Journal of Oncology, 2022, 2022: 7043431.
  • Lighting a Fire: Gasdermin-Mediated Pyroptosis Remodels the Glioma Microenvironment and Promotes Immune Checkpoint Blockade Response
    Cai, Yonghua; Li, Ke; Lin, Jie; Liang, Xianqiu; Xu, Wei; Zhan, Zhengming; Xue, Shuaishuai; Zeng, Yu; Chai, Peng; Mao, Yangqi; Song, Zibin; Han, Lei; Song, Ye*; Zhang, Xian*; Wang, Hai*Frontiers in Immunology, 2022, 13: 910490.被引 2
  • Development and validation of a pyroptosis-related genes signature for risk stratification in gliomas
    Sun, Penggang; Wang, Xinyu; Zhong, Junzhe; Yu, Daohan; Xuan, Hanwen; Xu, Tianye; Song, Dan; Yang, Changxiao; Wang, Pandeng; Liu, Yuxiang; Meng, Xiangqi*; Cai, Jinquan*Frontiers in Genetics, 2023, 14: 1087563.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-08-03
卷期
第 13 卷
页码
961933
DOI
10.3389/fimmu.2022.961933
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2021M701633]; National Natural Science Foundation of China [31871406, 82102730]; Funds for Construction of High-Level Universities in Guangdong Province; Natural Science Foundation of Guangdong Province [2021A1515011067]

作者

  • Z

    Zeng, Yu (第一作者)

    southern med univ

  • C

    Cai, Yonghua

    southern med univ

查看全部 18 位作者收起作者
  • C

    Chai, Peng

    southern med univ

  • M

    Mao, Yangqi

    southern med univ

  • C

    Chen, Yanwen

    southern med univ

  • W

    Wang, Li

    southern med univ

  • Z

    Zeng, Kunlin

    southern med univ

  • Z

    Zhan, Ziling

    southern med univ

  • X

    Xie, Yuxin

    southern med univ

  • L

    Li, Cuiying

    southern med univ

  • Z

    Zhan, Hongchao

    southern med univ

  • Z

    Zhao, Liqian

    southern med univ

  • C

    Chen, Xiaoxia

    southern med univ

  • Z

    Zhu, Xiaoxia

    southern med univ

  • L

    Liu, Yu

    shanghai jiao tong univ

  • C

    Chen, Ming (通讯)

    shanghai jiao tong univ

  • S

    Song, Ye (通讯)

    southern med univ

  • Z

    Zhou, Aidong (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417